Physician profile
Robert C Janda
NPI 1053426031
$6,723.02
in general payments reported to CMS, 2019-2025
36 companies · $270 in 2025
The $270 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,093 · 2020: $616 · 2021: $1,227 · 2022: $1,767 · 2023: $1,090 · 2024: $660 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,020.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,891.05 | 2019-2025 | |
| Janssen Biotech, INC. | $883.95 | 2019-2025 | Stelara, Tremfya, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $774.21 | 2019-2023 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $551.76 | 2019-2024 | Trulance, Xifaxan |
| Pfizer INC. | $302.58 | 2019-2023 | |
| Boston Scientific Corporation | $287.70 | 2024 | Watchman Flx, Exalt Model D |
| Gilead Sciences, INC. | $201.90 | 2019-2021 | |
| Celgene Corporation | $172.21 | 2021-2023 | Zeposia |
| Genzyme Corporation | $148.03 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $128.35 | 2024 | Iqirvo |
| E.R. Squibb & Sons, L.L.C. | $124.36 | 2021 | |
| Phathom Pharmaceuticals, INC. | $119.92 | 2024 | Voquezna |
| Exact Sciences Corporation | $107.78 | 2024 | Cologuard Collection Kit |
| Shire North American Group INC | $89.66 | 2019 | |
| Qol Medical, LLC | $89.54 | 2022-2023 | Sucraid |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $86.52 | 2021-2022 | |
| Ardelyx, INC. | $75.85 | 2022-2023 | Ibsrela |
| Braintree Laboratories, INC. | $74.90 | 2019-2022 | |
| Vivus LLC | $70.09 | 2020-2023 | Pancreaze |
| Evoke Pharma, INC. | $65.10 | 2021-2023 | Gimoti |
| Allergan, INC. | $58.85 | 2019 | |
| Ucb, INC. | $55.14 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $51.36 | 2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $44.03 | 2021-2022 | |
| Romark Laboratories, Lc | $39.43 | 2019-2020 | |
| Pentax of America, INC. | $36.49 | 2022 | |
| Redhill Biopharma INC. | $35.98 | 2022 | |
| Ironwood Pharmaceuticals, INC | $34.22 | 2019-2020 | |
| Dova Pharmaceuticals | $21.09 | 2019 | |
| Fresenius Kabi USA, LLC | $20.28 | 2023 | |
| Organon LLC | $19.84 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $17.11 | 2022 | |
| Sandoz INC. | $15.70 | 2023 | Hyrimoz |
| Alfasigma USA, INC. | $15.39 | 2021 | |
| Merck Sharp & Dohme LLC | $12.65 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$13,882.69 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Janda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.